Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastasios Dimou

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
JTO Clinical and Research Reports|May 8, 2025
Combination of Lurbinectedin and Osimertinib for Treatment of <i>EGFR</i>-Mutated Transformed SCLC: A Brief ReportAditi Singh, Arthi Sridhar, Aastha Poddar, et al.
Plos One|February 6, 2014
Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic diseaseYoung Kwang Chae, Danai Khemasuwan, Anastasios Dimou, et al.
Cancer|December 15, 2018
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancerTerry L Ng, Yiwei Liu, Anastasios Dimou, et al.
Frontiers in Immunology|February 19, 2025
Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanomaYuan Yao, Yiyi Yan, Vera J Suman, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 13, 2020
Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancerAnastasios Dimou, Cecile Nasarre, Yuri K Peterson, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 25, 2025
Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social supportRyan Brown, Katie E Smith, Mohamed M Shanshal, et al.
Sensors (Basel, Switzerland)|April 30, 2021
Drone vs. Bird Detection: Deep Learning Algorithms and Results from a Grand ChallengeAngelo Coluccia, Alessio Fascista, Arne Schumann, et al.
Melanoma Research|August 29, 2024
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital settingRonen Stoff, Svetomir N Markovic, Robert R McWilliams, et al.
Anticancer Research|April 13, 2016
HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group StudyThomas Makatsoris, Athanassios C Tsamandas, Alexios Strimpakos, et al.
Clinical Lung Cancer|October 25, 2023
Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung CancerAakash Desai, Caleb J Smith, Yash Ashara, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
JTO Clinical and Research Reports|May 8, 2025
Combination of Lurbinectedin and Osimertinib for Treatment of <i>EGFR</i>-Mutated Transformed SCLC: A Brief ReportAditi Singh, Arthi Sridhar, Aastha Poddar, et al.
Plos One|February 6, 2014
Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic diseaseYoung Kwang Chae, Danai Khemasuwan, Anastasios Dimou, et al.
Cancer|December 15, 2018
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancerTerry L Ng, Yiwei Liu, Anastasios Dimou, et al.
Frontiers in Immunology|February 19, 2025
Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanomaYuan Yao, Yiyi Yan, Vera J Suman, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 13, 2020
Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancerAnastasios Dimou, Cecile Nasarre, Yuri K Peterson, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 25, 2025
Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social supportRyan Brown, Katie E Smith, Mohamed M Shanshal, et al.
Sensors (Basel, Switzerland)|April 30, 2021
Drone vs. Bird Detection: Deep Learning Algorithms and Results from a Grand ChallengeAngelo Coluccia, Alessio Fascista, Arne Schumann, et al.
Melanoma Research|August 29, 2024
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital settingRonen Stoff, Svetomir N Markovic, Robert R McWilliams, et al.
Anticancer Research|April 13, 2016
HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group StudyThomas Makatsoris, Athanassios C Tsamandas, Alexios Strimpakos, et al.
Clinical Lung Cancer|October 25, 2023
Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung CancerAakash Desai, Caleb J Smith, Yash Ashara, et al.
Pageof 7